Aignostics published a new preprint introducing LUCAID, a multimodal, agentic AI system for lung cancer pathology.
Published
Signal category
Research & Knowledge
Quote
“Congratulations to our team and collaborators on a new preprint introducing LUCAID — a multimodal, agentic AI system for lung cancer pathology.”
— Aignostics team
Company
Aignostics
AI-powered precision diagnostics for pathology
- Industry
- Software Development
- Location
- Berlin, DE
- Company size
- 114 employees
Aignostics combines proprietary access to multimodal clinical datasets, industry-leading AI technologies, and rigorous science to develop best-in-class insights for the next generation of precision medicine. Through collaborations with its biopharma partners, Aignostics supports drug discovery, translational research, clinical trials, and CDx development across multiple therapeutic areas. Established in 2018, Aignostics is a spin-off from Charité Berlin, one of the world’s largest and most esteemed university hospitals. Aignostics is funded by leading VC investors and has operations in Berlin and New York.
Founded 2018